The Experts below are selected from a list of 222045 Experts worldwide ranked by ideXlab platform
Michel Ducreux - One of the best experts on this subject based on the ideXlab platform.
-
screening and surveillance in hereditary gastrointestinal cancers recommendations from the european society of digestive oncology esdo expert discussion at the 20th european society for medical oncology esmo world congress on gastrointestinal cancer barcelona june 2018
European Journal of Cancer, 2018Co-Authors: Deepak Vangala, Estelle Cauchin, Judith Balmana, Lucian Wyrwicz, Eric Van Cutsem, Ulrich Guller, Antoni Castells, Fatima Carneiro, Pascal Hammel, Michel DucreuxAbstract:Abstract Patients with hereditary gastrointestinal (GI) cancers represent a substantial fraction of the overall affected population. Although awareness for hereditary GI cancer syndromes is on the rise, identification of patients and measures of surveillance are often unclear in everyday Clinical Routine. Therefore, the European Society of Digestive Oncology expert discussion 2018 at the World Congress on Gastrointestinal Cancer focussed on screening and surveillance of hereditary colorectal, gastric and pancreatic cancers. An international panel of experts and opinion leaders developed the here presented recommendations based on published evidence and on profound Clinical expertise to facilitate Clinical Routine in identification and caretaking of patients with familial GI cancers.
-
Clinical relevance of molecular diagnostics in gastrointestinal gi cancer european society of digestive oncology esdo expert discussion and recommendations from the 17th european society for medical oncology esmo world congress on gastrointestinal cancer barcelona
European Journal of Cancer, 2017Co-Authors: Alexander Baraniskin, Lucian Wyrwicz, Ulrich Guller, Fatima Carneiro, Michel Ducreux, Jeanluc Van Laethem, Harpreet Wasan, Tamara Matysiakbudnik, Thomas Gruenberger, Eric Van CutsemAbstract:Abstract Background and scope In the epoch of precision medicine and personalised oncology, which aims to deliver the right treatment to the right patient, molecular genetic biomarkers are a topic of growing interest. The aim of this expert discussion and position paper is to review the current status of various molecular tests for gastrointestinal (GI) cancers and especially considering their significance for the Clinical Routine use. Methodology Opinion leaders and experts from diverse nationalities selected on scientific merit were asked to answer to a prepared set of questions about the current status of molecular diagnostics in different GI cancers. All answers were then discussed during a plenary session and reported here in providing a well-balanced reflection of both Clinical expertise and updated evidence-based medicine. Results Preselected molecular genetic biomarkers that are described and disputed in the current medical literature in different GI cancers were debated, and recommendations for Clinical Routine practice were made whenever possible. Furthermore, the preanalytical variations were commented and proposals for quality controls of biospecimens were made. Conclusion The current article summarises the recommendations of the expert committee regarding prognostic and predictive molecular genetic biomarkers in different entities of GI cancers. The briefly and comprehensively formulated guidelines should assist clinicians in the process of decision making in daily Clinical practice.
Eric Van Cutsem - One of the best experts on this subject based on the ideXlab platform.
-
screening and surveillance in hereditary gastrointestinal cancers recommendations from the european society of digestive oncology esdo expert discussion at the 20th european society for medical oncology esmo world congress on gastrointestinal cancer barcelona june 2018
European Journal of Cancer, 2018Co-Authors: Deepak Vangala, Estelle Cauchin, Judith Balmana, Lucian Wyrwicz, Eric Van Cutsem, Ulrich Guller, Antoni Castells, Fatima Carneiro, Pascal Hammel, Michel DucreuxAbstract:Abstract Patients with hereditary gastrointestinal (GI) cancers represent a substantial fraction of the overall affected population. Although awareness for hereditary GI cancer syndromes is on the rise, identification of patients and measures of surveillance are often unclear in everyday Clinical Routine. Therefore, the European Society of Digestive Oncology expert discussion 2018 at the World Congress on Gastrointestinal Cancer focussed on screening and surveillance of hereditary colorectal, gastric and pancreatic cancers. An international panel of experts and opinion leaders developed the here presented recommendations based on published evidence and on profound Clinical expertise to facilitate Clinical Routine in identification and caretaking of patients with familial GI cancers.
-
Clinical relevance of molecular diagnostics in gastrointestinal gi cancer european society of digestive oncology esdo expert discussion and recommendations from the 17th european society for medical oncology esmo world congress on gastrointestinal cancer barcelona
European Journal of Cancer, 2017Co-Authors: Alexander Baraniskin, Lucian Wyrwicz, Ulrich Guller, Fatima Carneiro, Michel Ducreux, Jeanluc Van Laethem, Harpreet Wasan, Tamara Matysiakbudnik, Thomas Gruenberger, Eric Van CutsemAbstract:Abstract Background and scope In the epoch of precision medicine and personalised oncology, which aims to deliver the right treatment to the right patient, molecular genetic biomarkers are a topic of growing interest. The aim of this expert discussion and position paper is to review the current status of various molecular tests for gastrointestinal (GI) cancers and especially considering their significance for the Clinical Routine use. Methodology Opinion leaders and experts from diverse nationalities selected on scientific merit were asked to answer to a prepared set of questions about the current status of molecular diagnostics in different GI cancers. All answers were then discussed during a plenary session and reported here in providing a well-balanced reflection of both Clinical expertise and updated evidence-based medicine. Results Preselected molecular genetic biomarkers that are described and disputed in the current medical literature in different GI cancers were debated, and recommendations for Clinical Routine practice were made whenever possible. Furthermore, the preanalytical variations were commented and proposals for quality controls of biospecimens were made. Conclusion The current article summarises the recommendations of the expert committee regarding prognostic and predictive molecular genetic biomarkers in different entities of GI cancers. The briefly and comprehensively formulated guidelines should assist clinicians in the process of decision making in daily Clinical practice.
Ottavio Giampietro - One of the best experts on this subject based on the ideXlab platform.
-
with regard to glycohemoglobin measurement are we sure that high performance liquid chromatography currently works in the Clinical Routine
Acta Diabetologica, 1998Co-Authors: Elena Matteucci, C Milioni, E Biasci, C Bertoni, E Boldrini, Ottavio GiampietroAbstract:The Clinical usefulness of glycated hemoglobin (HbA1c) depends crucially on the accuracy and precision of its assay. When we compared an immunological bench-top analyzer (DCA 2000, Bayer Diagnostici, Milan) to the high-performance liquid chromatography (HPLC) reference method used in a Routine hospital laboratory (Diamat and Fast Diamat, Bio-Rad Lab., Milan) by assaying multiple control sera, we found so many sources of systematic analytical errors in the Routine use of HPLC as to compromise between-assay precision. DCA 2000 showed intra- and interassay coefficients of variation (CV) of 1.1% and 2.3% with the normal standard serum, 1.0% and 4.2% with the pathological one; Diamat yielded CVs of 1.3% and 7.0%, 1.3% and 5.7%, respectively. Although the measurement of 161 blood samples showed that Diamat usually overestimated HbA1c (paired t-test, P<0.001), a great variability of Diamat performance became evident when the relationship Diamat vs DCA was evaluated day by day over 17 days of observation (analysis of variance, ANOVA, P<0.001). Intra- and interassay CVs of Fast Diamat initially (new instrument still on approval) were 0.6% and 2.5% (normal standard serum), 0.3% and 1.9% (high standard serum), yet after 6 months of Routine laboratory use, they became 3.1% and 3.2%, 1% and 12.3%, respectively. Main sources of error were: inaccurate autodilution, unsuitable parameter settings, disregard of the maintenance schedule. We conclude that the tendency to overlook major critical aspects in the Routine use of HPLC is detrimental to the quality of HbA1c determination and implies the loss of HbA1c value in Clinical practice. Both carefully supervising laboratory quality and checking the likelihood of the analytical result with the Clinical setting appear even more important.
Fatima Carneiro - One of the best experts on this subject based on the ideXlab platform.
-
screening and surveillance in hereditary gastrointestinal cancers recommendations from the european society of digestive oncology esdo expert discussion at the 20th european society for medical oncology esmo world congress on gastrointestinal cancer barcelona june 2018
European Journal of Cancer, 2018Co-Authors: Deepak Vangala, Estelle Cauchin, Judith Balmana, Lucian Wyrwicz, Eric Van Cutsem, Ulrich Guller, Antoni Castells, Fatima Carneiro, Pascal Hammel, Michel DucreuxAbstract:Abstract Patients with hereditary gastrointestinal (GI) cancers represent a substantial fraction of the overall affected population. Although awareness for hereditary GI cancer syndromes is on the rise, identification of patients and measures of surveillance are often unclear in everyday Clinical Routine. Therefore, the European Society of Digestive Oncology expert discussion 2018 at the World Congress on Gastrointestinal Cancer focussed on screening and surveillance of hereditary colorectal, gastric and pancreatic cancers. An international panel of experts and opinion leaders developed the here presented recommendations based on published evidence and on profound Clinical expertise to facilitate Clinical Routine in identification and caretaking of patients with familial GI cancers.
-
Clinical relevance of molecular diagnostics in gastrointestinal gi cancer european society of digestive oncology esdo expert discussion and recommendations from the 17th european society for medical oncology esmo world congress on gastrointestinal cancer barcelona
European Journal of Cancer, 2017Co-Authors: Alexander Baraniskin, Lucian Wyrwicz, Ulrich Guller, Fatima Carneiro, Michel Ducreux, Jeanluc Van Laethem, Harpreet Wasan, Tamara Matysiakbudnik, Thomas Gruenberger, Eric Van CutsemAbstract:Abstract Background and scope In the epoch of precision medicine and personalised oncology, which aims to deliver the right treatment to the right patient, molecular genetic biomarkers are a topic of growing interest. The aim of this expert discussion and position paper is to review the current status of various molecular tests for gastrointestinal (GI) cancers and especially considering their significance for the Clinical Routine use. Methodology Opinion leaders and experts from diverse nationalities selected on scientific merit were asked to answer to a prepared set of questions about the current status of molecular diagnostics in different GI cancers. All answers were then discussed during a plenary session and reported here in providing a well-balanced reflection of both Clinical expertise and updated evidence-based medicine. Results Preselected molecular genetic biomarkers that are described and disputed in the current medical literature in different GI cancers were debated, and recommendations for Clinical Routine practice were made whenever possible. Furthermore, the preanalytical variations were commented and proposals for quality controls of biospecimens were made. Conclusion The current article summarises the recommendations of the expert committee regarding prognostic and predictive molecular genetic biomarkers in different entities of GI cancers. The briefly and comprehensively formulated guidelines should assist clinicians in the process of decision making in daily Clinical practice.
Ulrich Guller - One of the best experts on this subject based on the ideXlab platform.
-
screening and surveillance in hereditary gastrointestinal cancers recommendations from the european society of digestive oncology esdo expert discussion at the 20th european society for medical oncology esmo world congress on gastrointestinal cancer barcelona june 2018
European Journal of Cancer, 2018Co-Authors: Deepak Vangala, Estelle Cauchin, Judith Balmana, Lucian Wyrwicz, Eric Van Cutsem, Ulrich Guller, Antoni Castells, Fatima Carneiro, Pascal Hammel, Michel DucreuxAbstract:Abstract Patients with hereditary gastrointestinal (GI) cancers represent a substantial fraction of the overall affected population. Although awareness for hereditary GI cancer syndromes is on the rise, identification of patients and measures of surveillance are often unclear in everyday Clinical Routine. Therefore, the European Society of Digestive Oncology expert discussion 2018 at the World Congress on Gastrointestinal Cancer focussed on screening and surveillance of hereditary colorectal, gastric and pancreatic cancers. An international panel of experts and opinion leaders developed the here presented recommendations based on published evidence and on profound Clinical expertise to facilitate Clinical Routine in identification and caretaking of patients with familial GI cancers.
-
Clinical relevance of molecular diagnostics in gastrointestinal gi cancer european society of digestive oncology esdo expert discussion and recommendations from the 17th european society for medical oncology esmo world congress on gastrointestinal cancer barcelona
European Journal of Cancer, 2017Co-Authors: Alexander Baraniskin, Lucian Wyrwicz, Ulrich Guller, Fatima Carneiro, Michel Ducreux, Jeanluc Van Laethem, Harpreet Wasan, Tamara Matysiakbudnik, Thomas Gruenberger, Eric Van CutsemAbstract:Abstract Background and scope In the epoch of precision medicine and personalised oncology, which aims to deliver the right treatment to the right patient, molecular genetic biomarkers are a topic of growing interest. The aim of this expert discussion and position paper is to review the current status of various molecular tests for gastrointestinal (GI) cancers and especially considering their significance for the Clinical Routine use. Methodology Opinion leaders and experts from diverse nationalities selected on scientific merit were asked to answer to a prepared set of questions about the current status of molecular diagnostics in different GI cancers. All answers were then discussed during a plenary session and reported here in providing a well-balanced reflection of both Clinical expertise and updated evidence-based medicine. Results Preselected molecular genetic biomarkers that are described and disputed in the current medical literature in different GI cancers were debated, and recommendations for Clinical Routine practice were made whenever possible. Furthermore, the preanalytical variations were commented and proposals for quality controls of biospecimens were made. Conclusion The current article summarises the recommendations of the expert committee regarding prognostic and predictive molecular genetic biomarkers in different entities of GI cancers. The briefly and comprehensively formulated guidelines should assist clinicians in the process of decision making in daily Clinical practice.
